CI heads into the back half of August with short sellers quietly rebuilding positions and the analyst community in an uneasy split following a bruising post-earnings reaction in late July.
The most notable shift this week is in short positioning. Bears have added meaningfully — short interest climbed 14% over the past week to 2.1% of the free float, roughly 5.7 million shares. That follows a period of relative calm through mid-August, and the acceleration is sharp enough to warrant attention even if the absolute level remains modest. The borrowing market is no constraint on further additions: availability is extraordinarily loose, with over 260 million shares available to borrow, and borrow cost has edged back up only marginally to 0.45% — barely above the low-fee range seen all month. The ORTEX short score has drifted higher to 33.4, its highest reading in the 10-day window, consistent with the directional rebuild. Options traders are moving the other way. The put/call ratio has dropped to 0.52, modestly below its 20-day average of 0.55 — meaning call demand is actually ticking up relative to recent norms. That mild divergence is worth noting: options positioning looks more constructive than short positioning does.
The Street is split in ways that explain the hesitation in the stock. Thirteen analysts carry buy-equivalent ratings versus five at hold, and the consensus mean target of $341 implies roughly 22% upside from the current $279. But the direction of recent analyst moves has been negative. Jefferies downgraded to Hold in early August, lowering its target to $307. Raymond James cut from Strong Buy to Outperform and trimmed its target to $320. Both downgrades came within days of each other after the Q2 print — when the stock fell nearly 6% on the day and extended that loss to around 7% over the following week. On the other side, Guggenheim raised its target to $361 and Bernstein sits at $381, maintaining the view that the selloff was overdone. Valuation remains a point of argument: the trailing P/E runs at 8.7x and EV/EBITDA at just 7.0x, levels that bulls point to as deeply discounted relative to earnings power. Bears counter with a challenging 2027 setup — soft medical loss ratios, the exit from the exchange market, margin pressure in the PBM and specialty pharmacy business, and an ongoing strategic review of EviCore.
Insider selling adds a modest note of caution. The Chief Administration Officer sold around $6.1 million worth of stock across two transactions in late July and mid-August. CEO David Cordani sold over $13 million in May across multiple tranches. These are routine-looking disposals in size and significance score, but the net 90-day insider flow is entirely negative — no buying on record — which at minimum means insiders have not been stepping in to defend the stock near current levels.
Among peers, the week has been mixed. HUM gained 2% on the week and UNH added 0.7%, while CVS dropped 2.1% and ASTH fell nearly 4%. CI's flat-to-marginal weekly gain of 0.3% keeps it in the middle of the peer pack — neither leading the recovery nor dragging significantly. With the next earnings event pencilled in for October 30, the key question between now and then is whether the short rebuild around 2% of float represents genuine conviction on the bear thesis around 2027 guidance, or simply tactical positioning ahead of what has become a reliably negative earnings-day reaction.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
